CV
Dr. rer. nat. Lisa Fröhlich
Academic education
2020 - 2023: Doctorate (Dr. rer. nat.) – Doctor in Biochemistry, Faculty of Mathematics and Natural Sciences, Department of Dermatooncology, University of Tübingen, Germany
2019 - 2020: Master of Science (MSc) – Master in Molecular Medicine, Faculty of Mathematics and Natural Sciences, University of Tübingen, Germany
2017 - 2018: Erasmsus Exchange Year, Pharmacy, University of Oslo, Norway
2015-2019: Bachelor of Science (BSc) – Bachelor in Molekularer Medizin, Faculty of Mathematics and Natural Sciences, University of Tübinge, Germany
Scientific degrees
01/2024: Dr. rer. nat. in Biochemistry, Faculty of Mathematics and Natural Sciences, University of Tübingen, Germany
09/2020: MSc in Molecular Medicine, Faculty of Mathematics and Natural Sciences, University of Tübingen, Germany
09/2019: BSc in Molekularer Medizin, Faculty of Mathematics and Natural Sciences, University of Tübingen, Germany
Scientific career
Since 11/2023: Postdoctoral Researcher at Department for Translational Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Parter Site Munich (Group of Prof. Dr. Martin Sos)
2020 - 2023: Doctorate (Dr. rer. nat.) – Doctor in Biochemistry, Faculty of Mathematics and Natural Sciences, Department of Dermatooncology, University of Tübingen, Germany
2019 - 2020: Master of Science (MSc) – Master in Molecular Medicine, Faculty of Mathematics and Natural Sciences, University of Tübingen, Germany
2015 - 2019: Bachelor of Science (BSc) – Bachelor in Molekularer Medizin, Faculty of Mathematics and Natural Sciences, University of Tübinge, Germany
Honors/ Awards/ Memberships:
2026: Recipient of a DFG Research Grant (Sachbeihilfe)
2025: Recipient of the “Stiftungen zu Gunsten der medizinischen Fakultät” Grant
2025: Poster Price at Workshop “Building Bridges in Munich Cancer Research”
2025: Young Investigator Award at 22nd International AEK Cancer Congress
2024: Best Talk Award at 11th Munich Cancer Retreat
2022: iFIT Excellence Cluster Poster Award
Contact Information
Dr. rer. nat. Lisa M. Fröhlich
Junior Group Leader
University of Cologne
Department for Translational Oncology
10 most relevant publications
- Lisa M. Fröhlich, Hannah L. Tumbrink, Bikash Adhikari, Margarita Rempe, JennyOstendorp, Paula Zickler, Pascal Hunold, Michaela Höhne-Wiechmann, AlenaHeimsoeth, Yichun Tang, Stefanie Lennartz, Ayla Schwäbe, Lisa Werr, Matthias Fischer, Alexander Quaas, Holger Grüll, Katia Garbert, Daniela Morgenthaler, Marian Touet, Johannes A. Hildebrand, Oliver Weigert, Filippo Beleggia, Dimitrios Papadopoulos, ElmarWolf, Johannes Brägelmann, Julia Frede, Robert Hänsel-Hertsch, Martin L. Sos bioRxiv 2026.08.19.745709; doi: 10.64898/2026.08.19.745709
- Mueller S, de Andrade Krätzig N, Tschurtschenthaler M, Silva MG, Thordsen C, Trozzo R, Simon P, Saab F, Kaltenbacher T, Zukowska M, Lucarelli D, Öllinger R, Griger J, Groß N, Groll T, Löprich J, Zaurito AE, Schömig LR, Bugter JM, Bärthel S, Falcomatà C, Strong A, Brandt C, Najajreh M, Papargyriou A, Maresch R, Collins KAN, Sailer D, Schneeweis C, Burger S, Fröhlich LM, Klement C, Belka A, Montero JJ, Jungwirth U, Reichert M, Moser M, Neumann J, Vassiliou G, Cadiñanos J, Varela I, Marr C, Alonso DF, Lollini PL, Zhao J, Chesler L, Isacke CM, Riedel A, Braun CJ, Sos ML, Beleggia F, Reinhardt HC, Musteanu M, Barbacid M, Quante M, Schmidt-Supprian M, Schneider G, Clare S, Lawley TD, Dougan G, Steiger K, Conte N, Bradley A, Rad L, Saur D, Rad R. A disease model resource reveals core principles of tissue-specific cancer evolution. Nature. 2026 May;653(8113):265-276. doi: 10.1038/s41586-026-10187-2. Epub 2026 Feb 25. PMID: 41741657; PMCID: PMC13149333.
- Fröhlich LM, Villar-Miyar A, Heintze T, Sauer B, Schittek B. PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma. Int J Cancer. 2024 Jul 15;155(2):203-210. doi: 10.1002/ijc.34947. Epub 2024 Apr 15. PMID: 38619111.
- Fröhlich LM, Niessner H, Sauer B, Kämereit S, Chatziioannou E, Riel S, Sinnberg T, Schittek B. PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo. Cancer Res Commun. 2023 Sep 5;3(9):1743-1755. doi: 10.1158/2767-9764.CRC-23-0101. PMID: 37674529; PMCID: PMC10478790.
- Fröhlich LM, Makino E, Sinnberg T, Schittek B. Enhanced expression of p21 promotes sensitivity of melanoma cells towards targeted therapies. Exp Dermatol. 2022 Aug;31(8):1243-1252. doi: 10.1111/exd.14585. Epub 2022 Jun 2. PMID: 35514255.
- Makino E, Fröhlich LM, Sinnberg T, Kosnopfel C, Sauer B, Garbe C, Schittek B. Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition. Cell Death Dis. 2020 Jul 2;11(7):581. doi: 10.1038/s41419-020-2702-y. PMID: 32719412; PMCID: PMC7385107.
